

LETTERS

Convincing tests

Independent reviews are said to have concluded that the planned National Ignition Facility would likely achieve "fusion ignition" and be useful for nuclear weapons "stockpile stewardship." "Animal teeth and bones" found along with Neandertal and Cro-Magnon remains are used to assist in the "molecular investigation" of the origins of humankind (right, a Neandertal skull from France). And methods for "precise editing of chromosomal and extrachromosomal sequences" in mouse and other mammalian cells are discussed.



NIF: "Harsh Light" or "Illumination"?

The News & Comment article "A harsh light falls on NIF" by James Glanz and with sidebars by him and Andrew Lawler (18 July, p. 304), is accurate and informative. The article does convey some of the excitement of laboratory fusion ignition and the sense that the National Ignition Facility (NIF) will have broad value for science. However, because of the title and some of the quotes selected early in the article, the sense of controversy is exaggerated. NIF is not a weapon, and its use for nuclear weapon assessment requires scientists to integrate results from laser-based experiments with computations and other experience; thus, judgments on NIF's use in stockpile stewardship may differ. Laboratory ignition has not been achieved and cannot be guaranteed; this can be used to suggest controversy, but many highly respected physicists are willing to bet their careers on ignition with NIF.

Because the mission value and the likelihood of full success of NIF require expert judgements, a number of independent reviews have been conducted since 1990, including those by the JASON group (twice), the Fusion Policy Advisory Committee, the 1990 National Academy of Sciences, and the Inertial Confinement Fusion Advisory Committee (several reports). These and other reviews represent significant effort by qualified scientists to examine the issues discussed in the article. The reviews have examined the issues from every perspective and have established a well-founded view that NIF will have significant value to stockpile stewardship and that ignition is likely. These reviews serve to reduce controversy on these issues, and they deserved more weight in the article.

Accomplishing the goals of NIF is a considerable challenge, as it should be. A

better theme for the article could have been, "Illuminating the NIF challenge."

David H. Crandall

Director, Office of Inertial

Fusion and the NIF,

U.S. Department of Energy,

Washington, DC 20585, USA

Neandertal Genetics

The recent discussion regarding Neandertal molecular studies (P. Kahn and A. Gibbons, *Research News*, 11 July, p. 176) suggests that other Neandertal and Cro-Magnon specimens should be examined for modern human mitochondrial haplotypes to further test multiregionalism (1). A Neandertal sequence from another site would also corroborate the initial study (2) and provide valuable data about the population structure of this temporally and spatially diverse group. To investigate the possibility that Paleolithic sites other than the Neander valley will be amenable to molecular investigation, we examined remains from four important Neandertal and Cro-Magnon sites in southern Europe, plus control samples of similar or younger age that are known to contain ancient DNA.

Contamination of preserved remains with modern human DNA is a significant problem in ancient DNA research (3), seriously complicating Neandertal studies (2). We avoided this problem by using relatively unimportant animal teeth and bones associated with Neandertal and Cro-Magnon remains as a proxy to determine the suitability of sites for molecular studies of human material. We analyzed several biochemical parameters indicative of diagenetic change (chemical modification associated with preservation processes) and DNA preservation (4, 5) before using an-

Instant
Information

研究者は
真のろ過を
求めています

**CADA DÍA,
FILTRAMOS LA
INFORMACIÓN MÁS
ACTUALIZADA PARA
LOS LABORATORIOS
DE TODO
EL MUNDO.**

**Where Labs
Go Daily
To Filter
The Facts.**

www.millipore.com

MILLIPORE

© 1997 Millipore Corporation

Circle No. 1 on Readers' Service Card

Table 1. Biochemical and histological data from Neandertal, Cro-Magnon, cold-preserved, and Holocene material. PCR reactions performed as described in (6) by using primers for 12S and control region*; 12S, cytochrome b, and control region†; 12S‡; and control region§. Histology scores range from 1 (poor) to 5 (good). N/A. experiment not performed.

Site	Age (kyr)	Taxa	Common name and sample	Aa racemization (D/L Asp, D/L Ala)	Aa (ppm)	% N	Histology (1–5)	Amplifiable DNA (bp)
<i>Neandertal</i>								
Zafarraya, Spain	33 (7)	<i>Capra pyrenaica</i>	Goat tooth	0.10, 0.04	2,750	0.07	1	No*
	"	"	Goat tooth	0.12, 0.04	3,400	0.25	1	No*
Krapina, Croatia	113 (8)	<i>Ursus spelaeus</i>	Bear tooth	0.16, N/A	900	0.18	N/A	No†
	"	"	Bear bone	0.17, 0.04	450	0.09	1	No†
	130 (8)	<i>Dicerorhinus mercki</i>	Rhino tooth	0.18, 0.03	700	0.36	N/A	No†
	"	"	Rhino bone	N/A, N/A	N/A	0.61	1	No†
	"	<i>Bison priscus</i>	Bison tooth	0.13, 0.02	7,600	0.54	1	No†
La Chaise, Suard, France	120–200 (12)	Neandertal	Neandertal bone	0.53, N/A	15	0.05	1	N/A
	"	"	Neandertal tooth	0.20, 0.05	700	0.15	1	N/A
	"	<i>Equus sp.</i>	Horse tooth	0.23, 0.07	80	0.02	1	No‡
<i>Cro-Magnon</i>								
Nerja, Spain	18 (13)	Cro-Magnon	<i>H. sapiens</i> tooth	0.36, 0.48	170	N/A	N/A	No§
	7–18 (13)	<i>Aves sp.</i>	Bird bone	0.14, 0.04	9,200	0.29	1	No‡
	"	<i>Aves sp.</i>	Bird bone	0.11, 0.34	17,200	0.21	1	No‡
<i>Holocene/permafrost</i>								
Barcelona, Spain	2	Modern human	<i>H. sapiens</i> tooth	0.10, 0.05	33,000	3.50	4	D-loop (120)
Otago, New Zealand	1–3 (14)	<i>Euryapteryx geranoides</i>	Bird bone	0.07, 0.02	79,000	3.80	5	12S, cyt b (300)
Canterbury, New Zealand	3.5 (14)	<i>Emeus crassus</i>	Bird bone	0.06, 0.02	57,000	4.32	5	12S, cyt b (300)
Fairbanks, Alaska	27 (5, 9)	<i>Equus hemionus</i>	Horse bone	0.07, 0.01	68,000	4.80	5	16S (140)
Shandrin, Siberia	35–40 (5, 9)	<i>Mammuthus primigenius</i>	Mammoth tissue	0.06, 0.01	98,000	N/A	5	16S (200)

How many
gel filtration
columns can you see?

(We count four.)

cient DNA techniques and the contamination-prone polymerase chain reaction (PCR) to amplify preserved DNA (6). PCR primers were designed to match faunal, but not human, sequences, removing the problem of modern human contamination.

We obtained faunal and human samples from three key Neandertal sites. Zafarraya, in southern Spain, is one of the youngest sites known (33,000 years old) (7), the Krapina collection from Croatia is the most extensive (110,000 to 130,000 years old) (8), and La Chaise is a classic Bordeaux site in France. Table 1 presents the results from analyses of Neandertal and Cro-Magnon sites, as well as from permafrost and Holocene controls. Samples from the Paleolithic sites are characterized by poor overall amino acid (Aa), nitrogen (N), and histological preservation and moderate to highly racemized aspartic acid (Asp) and alanine (Ala) residues. These values suggest extensive diagenetic modification (4, 5); correspondingly, we were not able to amplify authentic DNA from any of these specimens. In contrast, the permafrost and Holocene samples appear to have little diagenetic modification, and amplifications of short mitochondrial DNA (mtDNA) sequences can be reproducibly obtained from this material (5, 9).

The biochemical data indicate that material from these Neandertal sites, and even relatively young Mediterranean deposits, exhibit signs of considerable diagenetic change and appear unsuitable for DNA analysis. Therefore, preserved Neandertal DNA is likely to be rare, and the DNA in the type specimen may result from its unique preservation conditions. The Neander valley is one of the northernmost Neandertal sites known, and it is not far south of the limit of maximum glaciation during the late Pleistocene. Consequently, the site is likely to have experienced cold or periglacial conditions for the majority of the time since the skeleton was deposited. This is important because low temperatures are known to assist DNA preservation over long time periods (10), as shown by the data from the permafrost samples. In contrast, the Paleolithic sites in this study are from areas with elevated mean temperatures and, like other prehistoric remains in the Levant (11), show large amounts of diagenetic alteration.

These findings suggest that pre-Holocene hominid material from most southern European and northern African areas will be unsuitable for molecular analyses. Most Neandertal specimens are therefore unlikely to contain amplifiable DNA, and should only be subjected to destructive analysis

after associated faunal remains are investigated. Accordingly, further tests of the multiregionalist hypothesis using Neandertal DNA will be difficult at best.

Alan Cooper, Department of Biological Anthropology, University of Oxford, OX2 6QS, United Kingdom; E-mail: alan.cooper@bioanth.ox.ac.uk; **Hendrik N. Poinar**, **Svante Pääbo**, Zoological Institute, University of Munich, D-80021 Munich, Germany; **J. Radović**, Croatian Natural History Museum, Demetrova 1, 10000 Zagreb, Croatia; **A. Debénath**, Université de Perpignan, Laboratoire de Préhistoire, UMR 5590 du CNRS, Avenue Léon Jean Gregory, 66720 Tautavel, France; **Miguel Caparros**, **Cecilio Barroso-Ruiz**, Institut de Paleontologie Humaine, 1 rue René Panhard, Paris 75013, France; **Jaume Bertranpetit**, Laboratori d'Antropologia, Facultat de Biologia, Universitat de Barcelona, E-08028 Barcelona, Spain; **Christina Nielsen-Marsh**, **Robert E. M. Hedges**, Research Laboratory for Archaeology, University of Oxford; **Bryan Sykes**, Institute of Molecular Medicine, University of Oxford

References and Notes

1. A. Thorne and M. Wolpoff, *Sci. Am.* **266**, 28 (April 1992).
2. M. Krings et al., *Cell* **90**, 19 (1997).
3. A. Cooper, *Am. J. Hum. Genet.* **60**, 1001 (1997).

"Who would have thought a gel filtration column would make it so easy for me to get into Science," says Stacy, a post-doc working in New York City.

That may look like just one column, but it's not. You see, that's Superdex™ inside that column. Superdex gel filtration technology is based on the best of the underlying technologies of Sephadex®, Superose® and Sepharose®—each already proven in thousands of published research findings. So, inside a Superdex column, you get the best technologies.

The best qualities of three great technologies in one: **Superdex**

Superdex delivers extremely rapid separations, incredibly steep selectivity curves, and truly minimal non-specific interactions. So it's ideal for purifying oligonucleotides, peptides, proteins, or other major biomolecules. The ingenious combination of the properties of dextran and agarose makes Superdex ten times faster than comparable gel filtration media. The proof of this statement is defined in the new Pharmacia Biotech "Gel Filtration: Practices and Principles"—a seventh edition handbook (that's right, edition number seven).

We're sure you'll find a Superdex selectivity to satisfy your needs. After all, it's available in three selectivity ranges (prep grade in bulk). And it comes in packs and columns varying from trial-size scouting packs, through lab-to process-scale columns—many of which arrive pre-packed.

Find out more about Superdex. Give us a call: 1 (800) 526-3593 in the USA; +81 3492 6949 in Japan; +46 18 16 50 11 in Europe and the rest of the world. Or visit us on the Internet: <http://www.biotech.pharmacia.se>. We've got the best gel filtration technology solution for you.

Circle No. 53 on Readers' Service Card



**Pharmacia
Biotech**
Uppsala, Sweden. (And the rest of the world)



TIME MACHINE



THE NEW MINI-PREP 24 FOR AUTOMATED PLASMID MINI-PREPS

- **Fast**—up to 24 preps per hr, saving you valuable time.
- **High Purity**—sufficient for automated fluorescent and manual sequencing.
- **Easy Operation**—begin prep with direct loading of bacterial culture. No centrifugation step saves you time.
- **Consistent Results**—up to 6 µg of plasmid per ml. Quality DNA ... time and time again.

Call now to learn how the New Improved Mini-Prep 24 can give you quality DNA and save time by automating your plasmid DNA preps!

1-800-466-7949

MACCONNELL
RESEARCH

11339 Sorrento Valley Road
San Diego, CA 92121
(619) 452-2603 • Fax (619) 452-6753
www.macconnell.com

Circle No. 40 on Readers' Service Card

- R. E. M. Hedges, A. R. Millard, A. W. G. Pike, *J. Arch. Sci.* **22**, 201 (1995).
- H. N. Poinar, M. Höss, J. L. Bada, S. Pääbo, *Science* **272**, 864 (1996).
- DNA was extracted, amplified, and sequenced according to procedures described by A. Cooper [in *Avian Molecular Systematics and Evolution*, D. Mindell, Ed. (Academic Press, New York, 1997), pp. 345–373]. PCR primers specified 40 to 100 base pairs (bp) of mtDNA fragments. Larger amplifications were obtained from DNA extracts from the Holocene material and fresh tissue used as positive controls (data not shown). The PCR primer pairs were as follows. 12S, 12SE (L), ACCCACCTAGAGGAGCCTGTTC, and 12SL (H), GCTGGGGACGGCGGTATATAG; cytochrome b, L1 CCAACATCTCTGCTGTATG, and H2, GCTAGAAATAGCCTGTATG; control region, goat L1, TTACCCATGCATATAAGCA, and goat H2, TTTCACGCGGCATGGTGAAC, cow L1, GCCCATGCATATAAGCAAG, and cow H2, ACGCGGCATGGTAATTAAGC, rhino L1, ATCATCAATCCTTCCACTC, and rhino H2, TCACACCAATATTCCGG, bear DLoop 1 and DLoop 2 [M. Höss, M. Kohn, S. Pääbo, F. Knauer, W. Schröder, *Nature* **359**, 199 (1992)] and human L16209 and H16271 and L16287 and H16356 [O. Handt, M. Krings, R. H. Ward, S. Pääbo, *Am. J. Hum. Genet.* **59**, 368 (1996)], where L and H refer to light and heavy strands, respectively, and the 5'-3' sequence of the primers is given.
- J. J. Hublin, C. Barroso Ruiz, P. Medina Lara, M. Fontugne, J.-L. Reyss, *C. R. Acad. Sci. Paris* **321** IIa, 931 (1995).
- W. J. Rink, H. P. Schwarcz, F. H. Smith, J. Radović, *Nature* **378**, 24 (1995).
- P. G. Taylor, *Mol. Biol. Evol.* **13**, 283 (1996).
- T. Lindahl, *Nature* **365**, 700 (1993).
- S. Weiner and O. Bar-Yosef, *J. Arch. Sci.* **17**, 197 (1990).
- B. Blackwell, N. W. Rutter, A. Debénath, *Geoarchaeology* **5**, 121 (1990).
- D. Turbón, A. Pérez-Pérez, C. Stringer, *J. Hum. Evol.*, in press.
- A. Cooper and R. A. Cooper, *Proc. R. Soc. London Ser. B* **261**, 293 (1995).
- Financial support provided in part by the U.K. National Environment Research Council and the New Zealand Marsden Fund. We thank R. Ward and D. Penny for discussion.

Kahn and Gibbons discuss the findings of a team of molecular biologists led by Svante Pääbo—the sequencing of a tiny fragment of mtDNA from the upper arm bone of the original Neandertal skeleton, recovered from a limestone quarry in Germany in 1856. While this is an astounding technical breakthrough (it is difficult to recover DNA from ancient bone) and an important result, what it means with respect to modern human origins, and the Neandertals' relationship to us, remains open to question.

Molecular clock models are full of problematic assumptions. Leaving aside differences of opinion about the rate of base pair substitutions, how to calibrate a molecular clock (1), and whether or not mtDNA mutations are neutral (2), the fact that the Neandertal sequence (and it should be kept in mind that there is—to date—only one) differs from those of modern humans does not resolve the question of whether or not “moderns” and “Neandertals” were different species. This is the primary conclusion of the research, according to the Pääbo team (3). Continuity advocates (people who think

that Neandertals contributed genetically to people of western Eurasian ancestry) argue that differences were only subspecific (4). Harvard geneticist Maryellen Ruvolo is quoted as saying that the genetic variation between the modern and the Neandertal sequences is within the range of other single species of primates and that there is in fact no genetic “yardstick” that might allow us to define a species. A more convincing test of the implications of the Pääbo data would be to sequence mtDNA from an unambiguously modern early European (the suggested candidate, Cro-Magnon, has not been dated) or, better yet, from alleged archaic and modern human fossils from the Israeli cave sites of Skhul and Qafzeh (supposedly “modern”) and Kebara and Tabun (supposedly “Neandertals”). If the Israeli fossils all show differences with modern humans of the same order of magnitude of those between Neandertals and moderns, that would be compelling evidence that *all* Upper Pleistocene hominids diverge from moderns by about the same amount (evidence for continuity) and that the distinction between Neandertals and moderns in the Levant, at least, is without foundation.

That researchers cannot distinguish a “Neandertal” from a “modern human” might seem surprising to some, but there is little consensus on what these terms mean. Arizona State University researcher Catherine Willermet reexamined the criteria used to classify and describe Neandertal and early modern human skulls by continuity and replacement advocates and found that only 11% of the variables were common to both groups of workers (5). In short, continuity and replacement advocates are using different sets of variables to assess differences and similarities and are defining differently those variables held in common.

A single DNA sequence from a single, undated skeleton can be interpreted in many different ways. If we are to come up with a satisfactory explanation for our origins, it should reconcile pattern searches in archaeology and in human paleontology, as well as in molecular biology. Those who would argue that Neandertals became extinct without issue should show how it could have occurred without leaving traces of disjunction in the archaeological record and in fossils themselves.

G. A. Clark
Department of Anthropology,
Arizona State University,
Tempe AZ 85287-2402, USA
E-mail: gaclark@asu.edu

References

- R. Lewin, *Science* **241**, 1598 (1988); *ibid.*, p. 1756; G. Clark, *Am. Sci.* **81**, 4 (1993).
- R. Davis, S. Miller, D. Parker, *Proc. Natl. Acad. Sci.*

- U.S.A. 94, 4526 (1997).
3. M. Krings, A. Stone, S. Pääbo, *Cell* **90**, 19 (1997).
 4. G. Clark and J. Lindly, *Am. Anthropol.* **91**, 962 (1989); C. Brace, in *Conceptual Issues in Modern Human Origins Research*, G. Clark and C. Willermet, Eds. (de Gruyter, New York, 1997), pp. 11–27; M. Wolpoff and R. Caspari, in *ibid.*, pp. 28–44.
 5. C. Willermet and G. Clark *J. Hum. Evol.* **29**, 487 (1995); G. Clark and C. Willermet, *Cambridge Archaeol. J.* **5**, 153 (1995).
 6. G. Clark, in *The Middle Paleolithic: Adaptation, Behavior and Variability*, H. Dibble and P. Mellars, Eds. (Univ. of Pennsylvania Museum, Philadelphia, 1992), pp. 183–205.

Mouse Engineering

Eliot Marshall's article "The mouse that prompted a roar" (News, 4 July, p. 24) discusses some of the constraints faced by researchers using the Cre-loxP site-specific recombination system. In fact, there are alternatives to the Cre-loxP system that can be used in mice.

The FLP site-specific recombinase system will also mediate precise editing of chromosomal and extrachromosomal sequences in mammalian cells (1) and in mice (2). Although the relative efficiencies of FLP and Cre in specific murine tissues remain to be determined, FLP works well in many tissues of transgenic mice. Several groups have

found that FLP recombines chromosomal targets in murine embryonic stem cells less efficiently than does Cre, but it may be that relative efficiencies will be found to be different for other cell types or tissues.

The Salk Institute has obtained allowed claims for some applications of FLP in mammalian systems and will disseminate FLP-related research materials to the academic community under a simple Materials Transfer Agreement. It will not attempt to regulate or impede the transfer of FLP-related materials among researchers, and also offers nonexclusive commercial licenses under reasonable terms.

Stephen O'Gorman
Geffrey M. Wahl

Gene Expression Laboratory,
Salk Institute for Biological Studies,
Post Office Box 85800,
San Diego, CA 92186, USA
E-mail: ogorman@salk.edu
E-mail: wahl@salk.edu

References

1. S. O'Gorman, D. A. Fox, G. M. Wahl, *Science* **251**, 1351 (1991).
2. S. M. Dymecki, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 6191 (1996); S. O. Gorman, unpublished observations; A. Berns, personal communication.

(continued on page 1117)

HUMAN EMBRYONIC AND FETAL TISSUE

- ◆ Exclusively for biomedical research at universities and nonprofit scientific institutions.
- ◆ The laboratory has studied normal and abnormal development and provided tissue for 35 years.
- ◆ Most tissues are available for study.
- ◆ Tissues can be supplied from most gestational stages and from normal or abnormal specimens.
- ◆ Immediate processing includes rapid fixation, LN₂, balanced salt or medium as requested.
- ◆ Tissues shipped nationwide by overnight air are suitable for molecular biology, enzymology, receptor study, electron microscopy, etc.

For further information:

Phone 800-583-0671
FAX 800-583-0668

Please include an abstract of proposed research, preferably on PHS 398.


Circle No. 22 on Readers' Service Card

Glyko's FACE® technology makes carbohydrate analysis fast, reliable, and affordable

Glyko's FACE (Fluorophore Assisted Carbohydrate Electrophoresis) technology makes it possible for you to work with and analyze complex carbohydrates using the same technique you already use in your lab: polyacrylamide gel

electrophoresis. Now, in less than one day, you can perform profiling, composition, or sequencing experiments using FACE chemistry kits. Everything you

need is included: enzymes or release chemicals, fluorescent labeling



Example of a FACE gel profile of N-linked oligosaccharides released from a number of different glycoproteins

reagents, electrophoresis standards, controls, running buffers, precast polyacrylamide gels, and complete protocols.

The FACE Imager and Analytical Software

give you the ability to analyze, quantify, and document the results of n-linked and o-linked oligosaccharide profiling, monosaccharide composition and sequencing gels—without radio-labeling, staining, or exhaustive sample preparation.

FACE Recombinant Glycosidases Glyko continues to discover and clone more recombinant glycosidases than anyone else. Stringent quality

control and high specific activity assure predictable reaction times and consistent results. Glyko recombinant glycosidases can be used for your cell biology, biochemistry, or sequencing experiments

To order or to learn more about Glyko products, custom services, and international distributors, call toll free: **1 800 33 GLYKO** (334 5956) U.S. only, phone: 1 415 382 6653, or fax: 1 415 382 7889.

VISIT OUR WEB SITE:
<http://www.glyko.com>



Circle No. 66 on Readers' Service Card